Telomere shortening is associated to TRF1 and PARP1 overexpression in Duchenne muscular dystrophy

Neurobiology of Aging

Volumn 32, Issue 12, 2011, Pages 2190-2197

  Aguennouz, M'Hammed ^a   Vita, Gian Luca ^a   Messina, Sonia ^a   Cama, Annamaria ^a   Lanzano, Natalia ^a   Ciranni, Annamaria ^a   Rodolico, Carmelo ^a   Di Giorgio, Rosa Maria ^a   Vita, Giuseppe ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Duchenne muscular dystrophy; PARP1; Replicative senescence; Telomere shortening; TRF1

Indexed keywords

MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; TELOMERASE; TELOMERIC REPEAT BINDING FACTOR 1;

AGE; ARTICLE; CELL AGING; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DUCHENNE MUSCULAR DYSTROPHY; ENZYME INHIBITION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; INFANT; INFLAMMATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SKELETAL MUSCLE SATELLITE CELL; TELOMERE;

CHILD; CHILD, PRESCHOOL; GENE EXPRESSION REGULATION; HUMANS; INFANT; MUSCULAR DYSTROPHY, DUCHENNE; POLY(ADP-RIBOSE) POLYMERASES; QUADRICEPS MUSCLE; TELOMERE SHORTENING; TELOMERIC REPEAT BINDING PROTEIN 1;

EID: 80053640237     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2010.01.008     Document Type: Article

References (52)

1. Aguilar-Quesada R., Muñoz-Gámez J.A., Martín-Oliva D., Peralta-Leal A., Quiles-Pérez R., Rodríguez-Vargas J.M., Ruiz de Almodóvar M., Conde C., Ruiz-Extremera A., Oliver F.J. Modulation of transcription by PARP-1: consequences in carcinogenesis and inflammation. Curr. Med. Chem. 2007, 14:1179-1187.
2. Bellon M., Datta A., Brown M., Pouliquen J.F., Couppie P., Kazanji M., Nicot C. Increased expression of telomere length regulating factors TRF1, TRF2 and TIN2 in patients with adult T-cell leukemia. Int. J. Cancer 2006, 119:2090-2097.
3. Benetos A., Gardner J.P., Zureik M., Labat C., Xiaobin L., Adamopoulos C., Temmar M., Bean K.E., Thomas F., Aviv A. Short telomeres are associated with increased carotid atherosclerosis in hypertensive subjects. Hypertension 2004, 43:182-185.
4. Blasco M.A. Telomeres and human disease: ageing, cancer and beyond. Nat. Rev. Genet. 2005, 6:611-622.
5. Brouilette S., Singh R.K., Thompson J.R., Goodall A.H., Samani N.J. White cell telomere length and risk of premature myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 2003, 23:842-846.
6. Cong Y.S., Wright W.E., Shay J.W. Human telomerase and its regulation. Microbiol. Mol. Biol. Rev. 2002, 66:407-425.
7. Cook B.D., Dynek J.N., Chang W., Shostak G., Smith S. Role for the related poly(ADP-Ribose) polymerases tankyrase 1 and 2 at human telomeres. Mol. Cell. Biol. 2002, 22:332-342.
8. Dantzer F., Giraud-Panis M.J., Jaco I., Amé J.C., Schultz I., Blasco M., Koering C.E., Gilson E., Ménissier-de Murcia J., de Murcia G., Schreiber V. Functional interaction between poly(ADP-Ribose) polymerase 2 (PARP-2) and TRF2: PARP activity negatively regulates TRF2. Mol. Cell. Biol. 2004, 24:1595-1607.
9. De Boeck G., Forsyth R.G., Praet M., Hogendoorn P.C. Telomere-associated proteins: cross-talk between telomere maintenance and telomere-lengthening mechanisms. J. Pathol. 2009, 217:327-344.
10. de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev. 2005, 19:2100-2110.
11. Decary S., Mouly V., Hamida C.B., Sautet A., Barbet J.P., Butler-Browne G.S. Replicative potential and telomere length in human skeletal muscle: implications for satellite cell-mediated gene therapy. Hum. Gene Ther. 1997, 8:1429-1438.
12. Decary S., Hamida C.B., Mouly V., Barbet J.P., Hentati F., Butler-Browne G.S. Shorter telomeres in dystrophic muscle consistent with extensive regeneration in young children. Neuromuscul. Disord. 2000, 10:113-120.
13. Di Donna S., Mamchaoui K., Cooper R.N., Seigneurin-Venin S., Tremblay J., Butler-Browne G.S., Mouly V. Telomerase can extend the proliferative capacity of human myoblasts, but does not lead to their immortalization. Mol. Cancer Res. 2003, 1:643-653.
14. Dubowitz V., Sewry C.A. Muscle Biopsy 2007, Saunders Elsevier, Edinburgh. third ed.
15. Flores I., Benetti R., Blasco M.A. Telomerase regulation and stem cell behaviour. Curr. Opin. Cell. Biol. 2006, 18:254-260.
16. García S., Bodaño A., González A., Forteza J., Gómez-Reino J.J., Conde C. Partial protection against collagen antibody-induced arthritis in PARP-1 deficient mice. Arthritis Res. Ther. 2006, 8:R14.
17. García S., Bodaño A., Pablos J.L., Gómez-Reino J.J., Conde C. Poly(ADP-ribose) polymerase inhibition reduces tumor necrosis factor-induced inflammatory response in rheumatoid synovial fibroblasts. Ann. Rheum. Dis. 2008, 67:631-637.
18. Ghaffari S.H., Shayan-Asl N., Jamialahmadi A.H., Alimoghaddam K., Ghavamzadeh A. Telomerase activity and telomere length in patients with acute promyelocytic leukemia: indicative of proliferative activity, disease progression, and overall survival. Ann. Oncol. 2008, 19:1927-1934.
19. Hansson M., Zendehrokh N., Ohyashiki J., Ohyashiki K., Westman U.B., Roos G., Dejmek A. Telomerase activity in effusions: a comparison between telomere repeat amplification protocol in situ and conventional telomere repeat amplification protocol assay. Arch. Pathol. Lab. Med. 2008, 132:1896-1902.
20. Harley C.B., Futcher A.B., Greider C.W. Telomeres shorten during ageing of human fibroblasts. Nature 1990, 345:458-460.
21. Hashimoto Y., Murakami Y., Uemura K., Hayashidani Y., Sudo T., Ohge H., Fukuda E., Sueda T., Hiyama E. Detection of human telomerase reverse transcriptase (hTERT) expression in tissue and pancreatic juice from pancreatic cancer. Surgery 2008, 143:113-125.
22. Hnia K., Gayraud J., Hugon G., Ramonatxo M., De La Porte S., Matecki S., Mornet D. L-arginine decreases inflammation and modulates the nuclear factor-kappaB/matrix metalloproteinase cascade in mdx muscle fibers. Am. J. Pathol. 2008, 172:1509-1519.
23. Honig L.S., Schupf N., Lee J.H., Tang M.X., Mayeux R. Shorter telomeres are associated with mortality in those with APOE epsilon4 and dementia. Ann. Neurol. 2006, 60:181-187.
24. Kadi F., Ponsot E. The biology of satellite cells and telomeres in human skeletal muscle: effects of aging and physical activity. Scand. J. Med. Sci. Sports 2009, (September). [Epub ahead of print].
25. Kim N.W. Clinical implications of telomerase in cancer. Eur. J. Cancer 1997, 33:781-786.
26. Kim M.K., Kang M.R., Nam H.W., Bae Y.S., Kim Y.S., Chung I.K. Regulation of telomeric repeat binding factor 1 binding to telomeres by casein kinase 2-mediated phosphorylation. J. Biol. Chem. 2008, 283:14144-14152.
27. Lord C.J., Ashworth A. Targeted therapy for cancer using PARP inhibitors. Curr. Opin. Pharmacol. 2008, 8:363-369.
28. Lund T.C., Grange R.W., Lowe D.A. Telomere shortening in diaphragm and tibialis anterior muscles of aged mdx mice. Muscle Nerve 2007, 36:387-390.
29. Martin-Ruiz C., Dickinson H.O., Keys B., Rowan E., Kenny R.A., Von Zglinicki T. Telomere length predicts poststroke mortality, dementia, and cognitive decline. Ann. Neurol. 2006, 60:174-180.
30. Mazzorana M., Pinna L.A., Battistutta R. A structural insight into CK2 inhibition. Mol. Cell. Biochem. 2008, 316:57-62.
31. Messina S., Altavilla D., Aguennouz M., Seminara P., Minutoli L., Monici M.C., Bitto A., Mazzeo A., Marini H., Squadrito F., Vita G. Lipid peroxidation inhibition blunts nuclear factor-κB activation, reduces skeletal muscle degeneration, and enhances muscle function in mdx mice. Am. J. Pathol. 2006, 168:918-926.
32. Messina S., Bitto A., Aguennouz M., Minutoli L., Monici M.C., Altavilla D., Squadrito F., Vita G. Nuclear factor kappa-B blockade reduces skeletal muscle degeneration and enhances muscle function in mdx mice. Exp. Neurol. 2006, 198:234-241.
33. Messina S., Mazzeo A., Bitto A., Aguennouz M., Migliorato A., De Pasquale M.G., Minutoli L., Altavilla D., Zentilin L., Giacca M., Squadrito F., Vita G. VEGF overexpression via adeno-associated virus gene transfer promotes skeletal muscle regeneration and enhances muscle function in mdx mice. FASEB J. 2007, 21:3737-3746.
34. Messina S., Bitto A., Aguennouz M., Mazzeo A., Migliorato A., Polito F., Irrera N., Altavilla D., Vita G.L., Russo M., Naro A., De Pasquale M.G., Rizzuto E., Musarò A., Squadrito F., Vita G. Flavocoxid counteracts muscle necrosis and improves functional properties in mdx mice: A comparison study with methylprednisolone. Exp. Neurol. 2009, 220:349-358.
35. Morosetti R., Broccolini A., Sancricca C., Gliubizzi C., Gidaro T., Tonali P.A., Ricci E., Mirabella M. Increased aging in primary muscle cultures of sporadic inclusion-body myositis. Neurobiol. Aging 2008, 10.1016/j.neurobiolaging.2008.08.011.
36. Mota R., Sánchez-Bueno F., Berenguer-Pina J.J., Hernández-Espinosa D., Parrilla P., Yélamos J. Therapeutic treatment with poly(ADP-ribose) polymerase inhibitors attenuates the severity of acute pancreatitis and associated liver and lung injury. Br. J. Pharmacol. 2007, 151:998-1005.
37. Muramatsu Y., Ohishi T., Sakamoto M., Tsuruo T., Seimiya H. Cross-species difference in telomeric function of tankyrase 1. Cancer Sci. 2007, 98:850-857.
38. Oexle K., Zwirner A., Freudenberg K., Kohlschütter A., Speer A. Examination of telomere lengths in muscle tissue casts doubt on replicative aging as cause of progression in Duchenne muscular dystrophy. Pediatr. Res. 1997, 42:226-231.
39. Oh H., Wang S.C., Prahash A., Sano M., Moravec C.S., Taffet G.E., Michael L.H., Youker K.A., Entman M.L., Schneider M.D. Telomere attrition and Chk2 activation in human heart failure. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:5378-5383.
40. Peralta-Leal A., Rodríguez-Vargas J.M., Aguilar-Quesada R., Rodríguez M.I., Linares J.L., de Almodóvar M.R., Oliver F.J. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases. Free Radic. Biol. Med. 2009, 47:13-26.
41. Ponsot E., Lexell J., Kadi F. Skeletal muscle telomere length is not impaired in healthy physically active old women and men. Muscle Nerve 2008, 37:467-472.
42. Reddel R.R. Alternative lengthening of telomeres, telomerase, and cancer. Cancer Lett. 2003, 194:155-162.
43. Rodon J., Iniesta M.D., Papadopoulos K. Development of PARP inhibitors in oncology. Expert Opin. Investig. Drugs 2009, 18:31-43.
44. Sánchez-Fidalgo S., Villegas I., Martín A., Sánchez-Hidalgo M., Alarcón de la Lastra C. PARP inhibition reduces acute colonic inflammation in rats. Eur. J. Pharmacol. 2007, 563:216-223.
45. Schertzer J.D., Gehrig S.M., Ryall J.G., Lynch G.S. Modulation of insulin-like growth factor (IGF)-I and IGF-binding protein interactions enhances skeletal muscle regeneration and ameliorates the dystrophic pathology in mdx mice. Am. J. Pathol. 2007, 171:1180-1188.
46. Seigneurin-Venin S., Bernard V., Tremblay J.P. Telomerase allows the immortalization of T antigen-positive DMD myoblasts: a new source of cells for gene transfer application. Gene Ther. 2000, 7:619-623.
47. Shay J.W., Wright W.E. Telomeres are double-strand DNA breaks hidden from DNA damage responses. Mol. Cell. 2004, 14:420-421.
48. van Steensel B., de Lange T. Control of telomere length by the human telomeric protein TRF1. Nature 1997, 385:740-743.
49. von Zglinicki T. Oxidative stress shortens telomeres. Trends Biochem. Sci. 2002, 27:339-344.
50. Webster C., Blau H.M. Accelerated age-related decline in replicative life-span of Duchenne muscular dystrophy myoblasts: implications for cell and gene therapy. Somat. Cell. Mol. Genet. 1990, 16:557-565.
51. Zhang Y., Cao E.H., Qin J.F. Up-regulation of telomere-binding TRF1, TRF2 related to reactive oxygen species induced by As(2)O(3) in MGC-803 cells. Eur. J. Pharmacol. 2005, 516:1-9.
52. Zhu C.H., Mouly V., Cooper R.N., Mamchaoui K., Bigot A., Shay J.W., Di Santo J.P., Butler-Browne G.S., Wright W.E. Cellular senescence in human myoblasts is overcome by human telomerase reverse transcriptase and cyclin-dependent kinase 4: consequences in aging muscle and therapeutic strategies for muscular dystrophies. Aging Cell. 2007, 6:515-523.